purity testing comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-01. Numbers and descriptions here follow the published literature rather than marketing material.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
== Food preparation == Archaeological excavation of ceramic assemblages, pertaining to the Inca, reveal the variety of vessels used in their cuisine. In many excavations, of the ceramic assemblages found, about one tenth tend to be vessels. Ollas were used for cooking, boiling, and stewing, and were essential to Inca cuisine preparation. Ollas were used frequently, since boiling was one of the most repeated food preparation techniques. The vessel is characterized by its wide mouth, with a variety of bases, including the conical-based, round-bottomed, and pedestal-based forms. The Moche, a civilization inhabiting the region before the Inca, elevated olla production by implementing the paddle-and-anvil technique. This technique involved a stone being held on the inside of the vessel, while a wooden paddle was used to form the outside's shape. The practice of the paddle-and-anvil technique added an artistic aspect to the creation of ollas, as the technique provided plenty of flexibility and variation for designing unique vessels. This practice continued into the Inca time period. Other ceramic vessels could be associated with chicha production, which involves its own intricate system of preparation. El Shincal, located in the Argentinian province of Catamarcas, is a chicha production site observed in archaeological studies. Archaeologists have interpreted the purpose of the site as a location that solely caters to feasts and ceremonial events, rather than as a place of permanent settlement.
Four years later, in 1934, Minot, Murphy, and Whipple were awarded the Nobel Prize in Physiology or Medicine for their research. In the 1930s, the company also continued its expansion overseas. In 1934, Eli Lilly and Company Limited, the company's first overseas subsidiary, was established in London, and a manufacturing plant was opened in Basingstoke. In 1932, despite the economic challenges of the Great Depression, Lilly's sales rose to $13 million. The same year, Eli Lilly, eldest grandson of Col. Lilly who had joined the company in 1909, was named as the company's president, succeeding his father, who remained as chairman of the board until 1948. In his early years at the company, Eli was especially interested in improving production efficiency and introduced a number of labor-saving devices. He also introduced scientific management principles, implemented cost-savings measures that modernized the company, and expanded the company's research efforts and collaborations with university researchers. Thimerosal, developed by chemist Morris Kharasch at the University of Maryland in the late 1920s, was subsequently marketed by Lilly under the trade name Merthiolate as an antiseptic and preservative. In 1934, the firm opened two new facilities in Indianapolis on the McCarty Street complex: a replica of Lilly's 1876 laboratory and the new Lilly Research Laboratories, "one of the most fully equipped facilities in the world." As part of its research and product development process, Lilly also conducted clinical studies at Indianapolis City Hospital.
These are sympatholytic drugs that block the effects of beta adrenergic receptors while having little or no effect on alpha receptors. They are sometimes used to treat high blood pressure, atrial fibrillation, and congestive heart failure, but recent reviews have concluded that other types of drugs are usually superior for those purposes. Beta blockers may be a viable choice for other cardiovascular conditions, though, including angina and Marfan syndrome. They are also widely used to treat glaucoma, most commonly in the form of eyedrops. Because of their effects in reducing anxiety symptoms and tremor, they have sometimes been used by entertainers, public speakers, and athletes to reduce performance anxiety, although they are not medically approved for that purpose and are banned by the International Olympic Committee. However, the usefulness of beta blockers is limited by a range of serious side effects, including slowing of heart rate, a drop in blood pressure, asthma, and reactive hypoglycemia. The negative effects can be particularly severe in people with diabetes.
Correct functioning of agouti requires DNA methylation. Methylation occurs in six guanine-cytosine (GC) rich sequences in the 5’ long terminal repeat of the IAP element in the viable yellow mutation. Methylation on a gene causes the gene to not be expressed because it will cause the promoter to be turned off. In utero, the mother's diet can cause methylation or demethylation. When this area is unmethylated, ectopic expression of agouti occurs, and yellow phenotypes are shown because the phaeomelanin is expressed instead of eumelanin. When the region is methylated, agouti is expressed normally, and grey and brown phenotypes (eumelanin) occur. The epigenetic state of the IAP element is determined by the level of methylation, as individuals show a wide range of phenotypes based on their degree of DNA methylation. Increased methylation is correlated with increased expression of the normal agouti gene. Low levels of methylation can induce gene imprinting which results in offspring displaying consistent phenotypes to their parents, as ectopic expression of agouti is inherited through non-genomic mechanisms. DNA methylation is determined in utero by maternal nutrition and environmental exposure. Methyl is synthesized de novo but attained through the diet by folic acid, methionine, betaine, and choline, as these nutrients feed into a consistent metabolic pathway for methyl synthesis. Adequate zinc and vitamin B12 are required for methyl synthesis as they act as cofactors for transferring methyl groups.
Several immunodeficiency syndromes present clinical and laboratory characteristics of autoimmunity. The decreased ability of the immune system to clear infections in these patients may be responsible for causing autoimmunity through perpetual immune system activation. One example is common variable immunodeficiency (CVID), where multiple autoimmune diseases are seen, e.g., inflammatory bowel disease, autoimmune thrombocytopenia, and autoimmune thyroid disease. Familial hemophagocytic lymphohistiocytosis, an autosomal recessive primary immunodeficiency, is another example. Low blood levels of red blood cells, white blood cells, and platelets, rashes, lymph node enlargement, and enlargement of the liver and spleen are commonly seen in these patients. The presence of multiple uncleared viral infections due to a lack of perforin is thought to be responsible. In addition to chronic and/or recurrent infections, many autoimmune diseases, including arthritis, autoimmune hemolytic anemia, scleroderma, and type 1 diabetes, are also seen in X-linked agammaglobulinemia (XLA). Recurrent bacterial and fungal infections and chronic inflammation of the gut and lungs are seen in chronic granulomatous disease (CGD). CGD is caused by a decreased production of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase by neutrophils. Hypomorphic RAG mutations are seen in patients with midline granulomatous disease; an autoimmune disorder commonly occurring in patients with granulomatosis with polyangiitis and NK/T cell lymphomas.
Sources: en.wikipedia.org
There has yet to be any academic evidence for the idea that there were significant forces considered loyal to the old regime. Rather, the continued fighting which was seen after the flight of Ceaușescu is believed to have been a result of mistaken exchanges of fire from the general population and armed forces. There has been no academic evidence to suggest that Securitate units fought against the revolution. The origins of this story can be found in the speech given on 22 December by Army Captain Mihail Lupoi. During this speech, he asserts that it was only the Securitate who had shot protesters before the 22nd and that the Securitate needs to come onto the side of the army. This placed the deaths of protesters by the army onto the shoulders of the Securitate. But both the army and Securitate had shot and killed protesters before the 22nd. The vast majority of deaths came from the period between 22 and 25 December. On the 22nd, a small group of individuals which would later comprise the core of the National Salvation Front (Romanian: Frontul Salvării Naționale, FSN), called for a mass mobilisation of people for the defence of the television station. This call to arms resulted in the accumulation of army personnel, patriotic guards (both in and out of uniform) and armed civilians guarding the station. Later the same evening, there was an announcement that a convoy of anti-terrorist units were heading for the television centre. This was not so, but it added to the extremely tense environment which had been building since the flight of Ceaușescu.
=== 1967–1968: RoBee's and Marriott === In 1967, the Azar's Big Boy restaurant franchise started RoBee's House of Beef restaurants in Ft. Wayne, Indiana. The Marriott Corp., which had acquired Bob's Big Boy and the Big Boy trademark in 1967, acquired RoBee's in February 1968 with plans to expand nationwide. RoBee's franchises would first be offered to Big Boy franchisees to coincide with their existing Big Boy territory. At the time there were 13 RoBee's restaurants in six states. During the acquisition, in January 1968, the competing roast beef chain Arby's sued RoBee's for trademark infringement and (other similarities that it considered) unfair competition. Because "RoBee's" sounded too much like "Arby's" the settlement required a new brand name and Marriott wanted something recognizable. Big Boy founder Bob Wian, then sitting on Marriott's board of directors, was friends with Roy Rogers' agent and suggested that the company approach Rogers about the use of his name. Already interested in associating with a chain restaurant, Rogers was in similar discussions with another company when Marriott called. Nonetheless, he accepted Marriott's offer: Rogers would receive a licensing fee for use of his name and also be paid for personal appearances at the restaurants. The restaurants would be called "Roy Rogers Roast Beef Sandwich" restaurants, and despite Arby's complaints, it retained RoBee's building design and covered wagon logo design.
=== Preclinical === ASD-002 - a child-specific (non-acidic, sustained-release) anti-hyper excitatory ester prodrug of the potassium channel modulator NSAID mefenamic acid (MFA, approved as Ponstel) to prevent toddlers from becoming non-verbal (developmental language disorder, DLD) Bryostatin-1 (MW-904) – protein kinase C stimulant CJRB-303 (CJRB-901, MRx-0006) – bacteria replacement Debamestrocel (growth factor-producing stem cell therapy) – dopaminergic cell replacement therapy FIN-211 – bacteria replacement and gastrointestinal microbiome modulator Levophacetoperane (NLS-3; (R,R)-phacetoperone; methylphenidate reverse ester) – norepinephrine and dopamine reuptake inhibitor and psychostimulant LIT-001 – small-molecule oxytocin receptor agonist MBDB – serotonin and norepinephrine releasing agent and weak serotonin 5-HT1 and 5-HT2 receptor ligand (entactogen) Psilocin (PLZ-1015) – non-selective serotonin receptor agonist and psychedelic hallucinogen QBM-001 – undefined mechanism of action (allosteric channel modulator; putative neuroprotective and anti-inflammatory agent)
=== Insecticides === Parasites/bioinsecticides and chemical insecticides synergistically reduce fitness. Saddler et al., 2015 finds even An. gambiae with knockdown resistance (kdr) are more susceptible to DDT if they are first infected with Plasmodium berghei and Farenhorst et al., 2009 the same for Metarhizium robertsii or Beauveria bassiana. This is probably due to an effect found by Félix et al., 2010 and Stevenson et al., 2011: An. gambiae alters various activities – especially CYP6M2 – in response to P. berghei invasion. CYP6M2 is known to somehow produce pyrethroid resistance, and pyrethroids and DDT share a mechanism of action.
The phenomenon of exonization also represents a special case of de novo gene birth, in which, for example, often-repetitive intronic sequences acquire splice sites through mutation, leading to de novo exons. This was first described in 1994 in the context of Alu sequences found in the coding regions of primate mRNAs. Interestingly, such de novo exons are frequently found in minor splice variants, which may allow the evolutionary "testing" of novel sequences while retaining the functionality of the major splice variant(s). Still, it was thought by some that most or all eukaryotic proteins were constructed from a constrained pool of "starter type" exons. Using the sequence data available at the time, a 1991 review estimated the number of unique, ancestral eukaryotic exons to be < 60,000, while in 1992 a piece was published estimating that the vast majority of proteins belonged to no more than 1,000 families. Around the same time, however, the sequence of chromosome III of the budding yeast Saccharomyces cerevisiae was released, representing the first time an entire chromosome from any eukaryotic organism had been sequenced. Sequencing of the entire yeast nuclear genome was then completed by early 1996 through a massive, collaborative international effort. In his review of the yeast genome project, Bernard Dujon noted that the unexpected abundance of genes lacking any known homologs was perhaps the most striking finding of the entire project.
Sources: en.wikipedia.org
Damage during the emplacement surgery Damage during a thoracic surgery Chemical degradation of the silicone shell of the prosthesis Trauma: blunt trauma, penetrating trauma, blast trauma Mechanical pressure, e.g. capsular contracture and mammogram breast examination As a Class III medical device, the breast implant is an industrial product that eventually fails because of age and design flaws of material and manufacture; thus the rupture-and-deflation of a prosthetic breast is a medical-device failure resolved with the surgical explantation and replacement of the failed prosthetic breast with a new model of prosthetic breast. In that light, the Food and Drug Administration informed the women of the U.S. that breast implants are medical devices of finite shelf-life that wear out and fail. That the longer a woman has breast implants in her body — either saline solution or silicone gel — the greater the statistical likelihood of her experiencing the medical complications of the rupture-and-deflation failure of her prosthetic breasts. For Second-generation prosthetic breasts (silicone shell, single-lumen) designed in the 1970s, the rupture-deflation defect occurred at the rate of eight to fifteen per cent (8–15%) at the ten-year mark after the surgery; which occurred among fifteen to thirty per cent (15–30%) of the cohort of mammoplasty patients. The study Safety and Effectiveness of Mentor's MemoryGel Implants at 6 Years (2009) reported a medical-device rate of failure of one-point-one per cent (1.1%) at the six-year mark after the surgery.
=== United States === In the US, there can be stigma that hinders people with sickle cell disease from receiving necessary care; one element of this is attributed to racism as the majority of people with sickle cell disease are black. Due to this, in 1970, the Black Panther Party (also known as the Black Panther Party for Self Defense) opened dozens of free clinics across the U.S. where free Sickle Cell Disease tests were offered. Over the course of the 1970s, thousands of people, largely African-Americans, received testing at one of these clinics. In September 2017, the US Social Security Administration issued a policy interpretation ruling providing background information on sickle cell disease and a description of how Social Security evaluates the disease during its adjudication process for disability claims.
Obese individuals are predisposed to developing osteoarthritis, not only due to the excess mechanical load, but also due to the excess expression of soluble factors, that is, leptin and pro-inflammatory cytokines, which contribute to joint inflammation and cartilage destruction. As such, obese individuals are in an altered state, due to a metabolic insufficiency, which requires specific nutritional treatment capable of normalising the leptin production and reducing the systematic low-level inflammation, in order to reduce the harmful impact of these systematic mediators on the joint health.
Biko saw white racism in South Africa as the totality of the white power structure. He argued that under apartheid, white people not only participated in the oppression of black people but were also the main voices in opposition to that oppression. He thus argued that in dominating both the apartheid system and the anti-apartheid movement, white people totally controlled the political arena, leaving black people marginalised. He believed white people were able to dominate the anti-apartheid movement because of their access to resources, education, and privilege. He nevertheless thought that white South Africans were poorly suited to this role because they had not personally experienced the oppression that their black counterparts faced. Biko and his comrades regarded multi-racial anti-apartheid groups as unwittingly replicating the structure of apartheid because they contained whites in dominant positions of control. For this reason, Biko and the others did not participate in these multi-racial organisations. Instead, they called for an anti-apartheid programme that was controlled by black people. Although he called on sympathetic whites to reject any concept that they themselves could be spokespeople for the black majority, Biko nevertheless believed that they had a place in the anti-apartheid struggle, asking them to focus their efforts on convincing the wider white community on the inevitability of apartheid's fall. Biko clarified his position to Woods: "I don't reject liberalism as such or white liberals as such.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.